NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

TRVI

Trevi Therapeutics Inc

Jun 30 • 04:00PM ET

5.47

Dollar change -0.15
Percentage change -2.67	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA AMGN ABBV LLY REGN BIIB GILD NBIX VRTX BMRN

| Held by: VTI IWM VXF IWO VTWO PTH IBB DWAS VFMO XPH

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.45	Insider Own	41.36%	Shs Outstand	99.89M	Perf Week	-4.87%
Market Cap	651.72M	Forward P/E	-	EPS next Y	-0.55	Insider Trans	-0.18%	Shs Float	69.87M	Perf Month	-13.99%
Enterprise Value	549.42M	PEG	-	EPS next Q	-0.10	Inst Own	43.98%	Short Float	10.92%	Perf Quarter	-15.85%
Income	-47.35M	P/S	-	EPS this Y	7.67%	Inst Trans	9.09%	Short Ratio	4.36	Perf Half Y	36.75%
Sales	0.00M	P/B	5.49	EPS next Y	-26.55%	ROA	-51.03%	Short Interest	7.63M	Perf YTD	32.77%
Book/sh	1.00	P/C	6.31	EPS next 5Y	-13.45%	ROE	-55.12%	52W High	7.48 -26.87%	Perf Year	106.42%
Cash/sh	0.87	P/FCF	-	EPS past 3/5Y	31.87% 27.09%	ROIC	-47.28%	52W Low	2.36 131.78%	Perf 3Y	140.97%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.45% 7.52%	Perf 5Y	-4.70%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-32.72%	Oper. Margin	-	ATR (14)	0.37	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	15.38	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	35.36	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	15.38	EPS Q/Q	19.80%	SMA20	-10.70%	Beta	0.48	Target Price	20.20
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-13.34%	Rel Volume	0.86	Prev Close	5.62
Employees	26	LT Debt/Eq	0.01	Earnings	May 08 AMC	SMA200	18.49%	Avg Volume	1.75M	Price	5.47
IPO	May 07, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	26.83% -	Trades		Volume	1,496,559	Change	-2.67%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-25	Initiated	H.C. Wainwright	Buy	$21
Mar-10-25	Upgrade	Raymond James	Outperform → Strong Buy	$9 → $29
Mar-10-25	Reiterated	Needham	Buy	$8 → $25
Dec-12-24	Reiterated	H.C. Wainwright	Buy	$6 → $7.50
Sep-09-24	Resumed	Leerink Partners	Outperform	$6 → $7
Aug-30-24	Initiated	Raymond James	Outperform	$9
Aug-30-24	Initiated	H.C. Wainwright	Buy	$6
Jun-13-24	Initiated	Rodman & Renshaw	Buy	$7
Apr-12-23	Initiated	B. Riley Securities	Buy	$6
Nov-22-22	Initiated	SVB Leerink	Outperform	$6
Jun-03-19	Initiated	SVB Leerink	Outperform	$14
Jun-03-19	Initiated	Stifel	Buy	$20
Jun-03-19	Initiated	Needham	Buy	$18
Jun-03-19	Initiated	BMO Capital Markets	Outperform	$15

Show Previous Ratings

Jun-05-25 04:30PM	Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares (PR Newswire)
Jun-03-25 10:15PM	Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock (PR Newswire) -5.78% +10.59%
Jun-02-25 04:01PM	Trevi Therapeutics Announces Proposed Public Offering of Common Stock (PR Newswire)
07:00AM	Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough (PR Newswire)
Jun-01-25 04:00PM	Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough (PR Newswire)
02:52PM	Loading…
May-29-25 02:52PM	H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating (Insider Monkey)
07:30AM	Trevi Therapeutics to Participate in Upcoming June Conferences (PR Newswire)
May-20-25 07:00AM	Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough (PR Newswire)
May-14-25 09:55AM	Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High? (Zacks)
May-09-25 03:43AM	Trevi Therapeutics Inc (TRVI) Q1 2025 Earnings Call Highlights: Promising Trial Results and ... (GuruFocus.com)
May-08-25 04:05PM	Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates (PR Newswire)
May-01-25 04:05PM	Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025 (PR Newswire)
Apr-03-25 07:30AM	Trevi Therapeutics to Participate in Upcoming April Investor Conferences (PR Newswire)
Mar-26-25 07:00AM	Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board (GlobeNewswire)
Mar-19-25 07:36AM	Q4 2024 Trevi Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:02AM	Loading…
03:02AM	Trevi Therapeutics Inc (TRVI) Q4 2024 Earnings Call Highlights: Navigating Losses and Advancing ... (GuruFocus.com)
Mar-18-25 04:05PM	Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates (PR Newswire)
Mar-11-25 04:05PM	Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025 (PR Newswire)
Mar-10-25 11:30AM	Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps (Benzinga) +41.16%
06:00AM	Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough (PR Newswire)
Mar-09-25 04:00PM	Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough (PR Newswire)
Feb-27-25 07:30AM	Trevi Therapeutics to Participate in Upcoming March Investor Conferences (PR Newswire)
Feb-26-25 10:47AM	Trevi Therapeutics enrols all subjects in trial of Haduvio for chronic cough in IPF (Clinical Trials Arena)
Feb-25-25 07:30AM	Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough (PR Newswire)
Feb-20-25 02:30PM	Why Trevi Therapeutics (TRVI) Is Advancing Today (Insider Monkey) +5.03%
Jan-30-25 07:30AM	Trevi Therapeutics to Participate in Upcoming February Investor Conferences (PR Newswire)
Jan-08-25 12:00PM	What Makes Trevi Therapeutics (TRVI) a New Buy Stock (Zacks)
07:30AM	Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference (PR Newswire)
Dec-16-24 07:36AM	Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering (PR Newswire)
Dec-13-24 07:10AM	Trevis chronic cough trial in IPF subjects continues without sample size change (Clinical Trials Arena) +15.83%
09:47AM	Loading…
Dec-12-24 09:47AM	Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday? (Benzinga) +44.58%
07:30AM	Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough (PR Newswire)
Dec-03-24 04:05PM	Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine (PR Newswire) -6.47%
Nov-21-24 07:30AM	Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference (PR Newswire)
Nov-07-24 01:18PM	Q3 2024 Trevi Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -6.45%
02:21AM	Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ... (GuruFocus.com)
Nov-06-24 04:05PM	Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates (PR Newswire)
Oct-30-24 04:05PM	Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 (PR Newswire)
Oct-23-24 05:02PM	Rosalind Advisors, Inc. Reduces Stake in Trevi Therapeutics Inc. (GuruFocus.com)
Oct-21-24 07:30AM	Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough (PR Newswire) +7.37%
Oct-15-24 07:30AM	Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences (PR Newswire)
Oct-09-24 05:58PM	Trevi Therapeutics Inc (TRVI) Q2 2024 Earnings Call Highlights: Navigating Financial Challenges ... (GuruFocus.com) -5.08%
Oct-03-24 04:05PM	Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program (PR Newswire) -5.33%
Sep-30-24 05:30PM	Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer (PR Newswire) -6.89%
Sep-26-24 07:30AM	Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024 (PR Newswire)
Sep-04-24 04:05PM	Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 (PR Newswire) +5.08%
Aug-30-24 09:33AM	Abercrombie upgraded, Dollar General downgraded: Wall Street's top analyst calls (The Fly) +8.59%
Aug-28-24 07:30AM	Trevi Therapeutics to Participate in September Investor and Medical Conferences (PR Newswire)
Aug-08-24 09:58PM	TRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q2 2024 (InvestorPlace) +8.11%
04:05PM	Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance (PR Newswire)
Aug-01-24 07:30AM	Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024 (PR Newswire)
Jul-02-24 07:30AM	Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events (PR Newswire) -7.27%
May-13-24 08:57AM	Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 07:30AM	Trevi Therapeutics to Participate in Upcoming Conferences (PR Newswire) +10.61%
May-08-24 06:56AM	Q1 2024 Trevi Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -8.97%
May-07-24 08:59PM	TRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
06:25PM	Trevi Therapeutics Reports Q1 2024 Financial Results: A Detailed Analysis (GuruFocus.com)
04:05PM	Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (PR Newswire)
May-01-24 04:05PM	Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024 (PR Newswire) +5.24%
Apr-18-24 09:55AM	Trevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Apr-09-24 07:30AM	Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference (PR Newswire) -8.13%
Apr-04-24 08:30AM	Why Trevi Therapeutics (TRVI) Stock Might be a Great Pick (Zacks)
07:30AM	Trevi Therapeutics to Participate in Upcoming April Events (PR Newswire)
Apr-02-24 07:30AM	Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team (PR Newswire)
Mar-21-24 10:46AM	Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-20-24 08:53PM	TRVI Stock Earnings: Trevi Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
05:33PM	Trevi Therapeutics Inc (TRVI) Announces Year-End Financials and Progress in Clinical Trials (GuruFocus.com)
04:05PM	Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates (PR Newswire)
Mar-13-24 04:05PM	Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024 (PR Newswire) +5.39%
Feb-28-24 07:30AM	Trevi Therapeutics to Participate in Upcoming March Events (PR Newswire) +5.78%
Feb-06-24 07:30AM	Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (PR Newswire)
Jan-17-24 12:00PM	Trevi Therapeutics, Inc. (TRVI) Upgraded to Strong Buy: Here's Why (Zacks)
Jan-04-24 07:30AM	Trevi Therapeutics Provides Business Updates (PR Newswire) +5.34%
Dec-05-23 07:30AM	Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) (PR Newswire)
Nov-30-23 09:35AM	Down -38.07% in 4 Weeks, Here's Why You Should You Buy the Dip in Trevi Therapeutics, Inc. (TRVI) (Zacks)
Nov-14-23 09:55AM	Trevi Therapeutics, Inc. (TRVI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks) +6.72%
09:35AM	After Plunging -28.72% in 4 Weeks, Here's Why the Trend Might Reverse for Trevi Therapeutics, Inc. (TRVI) (Zacks)
Nov-12-23 11:13AM	Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:05PM	Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Nov-02-23 07:30AM	Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio for Refractory Chronic Cough (PR Newswire) -5.68%
Nov-01-23 04:05PM	Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023 (PR Newswire)
Oct-13-23 08:30AM	Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio in Prurigo Nodularis (PR Newswire)
Oct-11-23 12:00PM	Trevi Therapeutics, Inc. (TRVI) Upgraded to Buy: Here's What You Should Know (Zacks)
Sep-06-23 07:30AM	Trevi Therapeutics to Participate in Upcoming September Events (PR Newswire)
Aug-12-23 08:30AM	Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-11-23 06:44AM	Q2 2023 Trevi Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 04:05PM	Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Aug-03-23 04:05PM	Trevi Therapeutics to Report Q2 2023 Financial Results and Provide a Corporate Update on August 10, 2023 (PR Newswire)
Aug-01-23 07:30AM	Trevi Therapeutics to Participate in Upcoming August Events (PR Newswire)
Jul-06-23 07:30AM	Trevi Therapeutics to Participate in Upcoming July Investor Events (PR Newswire)
Jun-04-23 10:45AM	Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) top owners are private equity firms with 35% stake, while 32% is held by hedge funds (Simply Wall St.)
May-30-23 07:30AM	Trevi Therapeutics to Participate in Upcoming June Conferences (PR Newswire) -14.81%
May-22-23 04:05PM	Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence (PR Newswire) -5.00% +5.26%
May-16-23 11:46AM	Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-12-23 06:38AM	Q1 2023 Trevi Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -5.67%
May-11-23 04:05PM	Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
May-10-23 08:48AM	Is a Surprise Coming for Trevi Therapeutics (TRVI) This Earnings Season? (Zacks)
May-09-23 07:30AM	Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023 (PR Newswire)
May-04-23 04:05PM	Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023 (PR Newswire)
May-02-23 07:30AM	Trevi Therapeutics Announces Two Presentations on the Phase 2 CANAL Data at the ATS 2023 International Conference (PR Newswire)

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SCIASCIA THOMAS	Chief Scientific Officer	Mar 25 '25	Option Exercise	1.43	2,631	3,762	224,004	Mar 26 04:30 PM
SCIASCIA THOMAS	Chief Scientific Officer	Mar 25 '25	Sale	6.60	2,631	17,365	221,373	Mar 26 04:30 PM
GOOD JENNIFER L	President & CEO	Mar 21 '25	Option Exercise	1.43	5,263	7,526	218,576	Mar 25 04:30 PM
GOOD JENNIFER L	President & CEO	Mar 21 '25	Sale	6.58	5,263	34,625	213,313	Mar 25 04:30 PM
GOOD JENNIFER L	Officer	Mar 21 '25	Proposed Sale	6.58	5,263	34,625		Mar 21 04:13 PM
Simon Farrell	Chief Commercial Officer	Mar 10 '25	Option Exercise	2.86	112,563	321,653	158,213	Mar 12 04:00 PM
Simon Farrell	Chief Commercial Officer	Mar 10 '25	Sale	6.75	81,313	548,878	76,900	Mar 12 04:00 PM
Simon Farrell	Officer	Mar 10 '25	Proposed Sale	6.75	81,313	548,880		Mar 10 04:32 PM
Delfini Lisa	Chief Financial Officer	Jan 08 '25	Option Exercise	0.51	5,000	2,555	64,660	Jan 10 04:14 PM
Delfini Lisa	Chief Financial Officer	Jan 07 '25	Option Exercise	0.51	1,000	511	59,660	Jan 10 04:14 PM
Galletta Christopher	See Remarks	Dec 13 '24	Option Exercise	0.51	15,000	7,665	19,935	Dec 17 04:30 PM
GOOD JENNIFER L	President & CEO	Sep 06 '24	Option Exercise	1.43	4,219	6,033	217,532	Sep 09 05:00 PM
GOOD JENNIFER L	President & CEO	Sep 09 '24	Option Exercise	1.43	1,840	2,631	215,153	Sep 09 05:00 PM
GOOD JENNIFER L	President & CEO	Sep 06 '24	Sale	3.03	4,219	12,784	213,313	Sep 09 05:00 PM
GOOD JENNIFER L	President & CEO	Sep 09 '24	Sale	3.04	1,840	5,587	213,313	Sep 09 05:00 PM
GOOD JENNIFER L	President & CEO	Sep 05 '24	Option Exercise	1.43	40,277	57,596	253,590	Sep 05 04:54 PM
GOOD JENNIFER L	President & CEO	Sep 04 '24	Option Exercise	1.43	10,981	15,703	224,294	Sep 05 04:54 PM
GOOD JENNIFER L	President & CEO	Sep 03 '24	Option Exercise	1.43	3,863	5,524	217,176	Sep 05 04:54 PM
GOOD JENNIFER L	President & CEO	Sep 05 '24	Sale	3.11	40,277	125,310	213,313	Sep 05 04:54 PM
GOOD JENNIFER L	President & CEO	Sep 04 '24	Sale	3.02	10,981	33,205	213,313	Sep 05 04:54 PM
GOOD JENNIFER L	President & CEO	Sep 03 '24	Sale	3.02	3,863	11,677	213,313	Sep 05 04:54 PM
GOOD JENNIFER L	Officer	Sep 03 '24	Proposed Sale	3.16	61,180	193,328		Sep 03 04:37 PM
Meeker David P	Director	Aug 27 '24	Option Exercise	1.43	4,555	6,514	357,044	Aug 29 04:55 PM
Meeker David P	Director	Aug 27 '24	Sale	2.93	4,555	13,353	352,489	Aug 29 04:55 PM
Meeker David P	Officer	Aug 27 '24	Proposed Sale	2.98	4,555	13,573		Aug 27 04:10 PM
SCIASCIA THOMAS	Chief Scientific Officer	Aug 19 '24	Option Exercise	1.43	16,496	23,589	236,811	Aug 21 04:00 PM
SCIASCIA THOMAS	Chief Scientific Officer	Aug 19 '24	Sale	2.96	16,496	48,883	220,315	Aug 21 04:00 PM
SCIASCIA THOMAS	Chief Scientific Officer	Aug 16 '24	Option Exercise	1.43	18,660	26,684	238,975	Aug 16 04:47 PM
SCIASCIA THOMAS	Chief Scientific Officer	Aug 15 '24	Option Exercise	1.43	12,745	18,225	233,060	Aug 16 04:47 PM
SCIASCIA THOMAS	Chief Scientific Officer	Aug 14 '24	Option Exercise	1.43	100	143	220,415	Aug 16 04:47 PM
SCIASCIA THOMAS	Chief Scientific Officer	Aug 16 '24	Sale	2.76	18,660	51,440	220,315	Aug 16 04:47 PM
SCIASCIA THOMAS	Chief Scientific Officer	Aug 15 '24	Sale	2.79	12,745	35,513	220,315	Aug 16 04:47 PM
SCIASCIA THOMAS	Chief Scientific Officer	Aug 14 '24	Sale	2.75	100	275	220,315	Aug 16 04:47 PM
SCIASCIA THOMAS	Officer	Aug 15 '24	Proposed Sale	2.61	48,001	125,282		Aug 15 04:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TRVI

Trevi Therapeutics Inc

Upgrade your FINVIZ experience